Access the full text.
Sign up today, get DeepDyve free for 14 days.
B. Norquist, Rochelle Garcia, K. Allison, C. Jokinen, L. Kernochan, Catherine Pizzi, Bethany Barrow, B. Goff, E. Swisher (2010)The molecular pathogenesis of hereditary ovarian carcinoma
N. Mavaddat, S. Peock, D. Frost, Steve Ellis, Radka Platte, E. Fineberg, D. Evans, L. Izatt, R. Eeles, J. Adlard, R. Davidson, D. Eccles, T. Cole, J. Cook, C. Brewer, M. Tischkowitz, F. Douglas, S. Hodgson, L. Walker, M. Porteous, Patrick Morrison, L. Side, M. Kennedy, C. Houghton, A. Donaldson, M. Rogers, H. Dorkins, Z. Miedzybrodzka, H. Gregory, J. Eason, J. Barwell, E. McCann, A. Murray, A. Antoniou, D. Easton (2013)Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
Journal of the National Cancer Institute, 105 11
M. Mingels, M. Ham, I. Kievit, M. Snijders, A. Tilborg, J. Bulten, L. Massuger (2014)Müllerian precursor lesions in serous ovarian cancer patients: using the SEE-Fim and SEE-End protocol
Modern Pathology, 27
Yonghee Lee, A. Miron, R. Drapkin, M. Nucci, Felipe Medeiros, Aasia Saleemuddin, J. Garber, C. Birch, H. Mou, R. Gordon, D. Cramer, F. McKeon, C. Crum (2007)A candidate precursor to serous carcinoma that originates in the distal fallopian tube
The Journal of Pathology, 211
M. Daly, R. Pilarski, Michael Berry, S. Buys, Meagan Farmer, S. Friedman, J. Garber, N. Kauff, S. Khan, C. Klein, W. Kohlmann, A. Kurian, J. Litton, L. Madlensky, S. Merajver, K. Offit, T. Pal, Gwen Reiser, K. Shannon, E. Swisher, S. Vinayak, Nicoleta Voian, J. Weitzel, M. Wick, G. Wiesner, M. Dwyer, S. Darlow (2017)NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.
Journal of the National Comprehensive Cancer Network : JNCCN, 15 1
David Portnoy, J. Loud, P. Han, P. Mai, M. Greene (2014)Effects of false-positive cancer screenings and cancer worry on risk-reducing surgery among BRCA1/2 carriers.
Health psychology : official journal of the Division of Health Psychology, American Psychological Association, 34 7
P. Snaith (2003)The Hospital Anxiety And Depression Scale
Health and Quality of Life Outcomes, 1
K. Kuchenbaecker, J. Hopper, D. Barnes, K. Phillips, T. Mooij, M. Roos-Blom, Sarah Jervis, F. Leeuwen, R. Milne, N. Andrieu, D. Goldgar, M. Terry, M. Rookus, D. Easton, A. Antoniou, L. McGuffog, D. Evans, D. Barrowdale, D. Frost, J. Adlard, K. Ong, L. Izatt, M. Tischkowitz, R. Eeles, R. Davidson, S. Hodgson, Steve Ellis, C. Noguès, C. Lasset, D. Stoppa-Lyonnet, J. Fricker, L. Faivre, P. Berthet, M. Hooning, L. Kolk, C. Kets, M. Adank, E. John, Wendy Chung, I. Andrulis, M. Southey, M. Daly, S. Buys, A. Osorio, C. Engel, K. Kast, R. Schmutzler, T. Caldés, A. Jakubowska, J. Simard, M. Friedlander, S. McLachlan, E. Macháčková, L. Foretova, Y. Tan, C. Singer, E. Oláh, A. Gerdes, B. Arver, H. Olsson (2017)Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
A. Stern (2014)The hospital anxiety and depression scale.
Occupational medicine, 64 5
P. Paley, E. Swisher, Rochelle Garcia, S. Agoff, B. Greer, Ksenia Peters, B. Goff (2001)Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis.
Gynecologic oncology, 80 2
D. Nebgen, J. Hurteau, L. Holman, A. Bradford, M. Munsell, Beth Soletsky, Charlotte Sun, G. Chisholm, K. Lu (2018)Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations.
Gynecologic oncology, 150 1
W. Rocca, B. Grossardt, M. Andrade, G. Malkasian, L. Melton (2006)Survival patterns after oophorectomy in premenopausal women: a population-based cohort study.
The Lancet. Oncology, 7 10
A. Finch, K. Metcalfe, J. Lui, C. Springate, R. Demsky, S. Armel, B. Rosen, J. Murphy, L. Elit, P. Sun, S. Narod (2009)Breast and ovarian cancer risk perception after prophylactic salpingo‐oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene
Clinical Genetics, 75
A. Antoniou, P. Pharoah, S. Narod, H. Risch, J. Eyfjord, J. Hopper, N. Loman, Hampus Olsson, O. Johannsson, Å. Borg, B. Pasini, P. Radice, S. Manoukian, D. Eccles, N. Tang, E. Oláh, H. Anton-Culver, E. Warner, J. Lubiński, J. Gronwald, B. Górski, H. Tulinius, S. Thorlacius, H. Eerola, H. Nevanlinna, K. Syrjäkoski, O. Kallioniemi, Deborah Thompson, Chris Evans, J. Peto, F. Lalloo, D. Evans, D. Easton (2003)Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
American journal of human genetics, 72 5
Yonghee Lee, F. Medeiros, D. Kindelberger, M. Callahan, M. Muto, C. Crum (2006)Advances in the Recognition of Tubal Intraepithelial Carcinoma: Applications to Cancer Screening and the Pathogenesis of Ovarian Cancer
Advances in Anatomic Pathology, 13
S. Gordhandas, B. Norquist, K. Pennington, R. Yung, M. Laya, E. Swisher (2019)Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.
Gynecologic oncology, 153 1
Marline Harmsen, M. Jong, N. Hoogerbrugge, A. Maas, J. Prins, J. Bulten, S. Teerenstra, E. Adang, J. Piek, H. Doorn, M. Beurden, M. Mourits, R. Zweemer, K. Gaarenstroom, B. Slangen, M. Vos, L. Lonkhuijzen, L. Massuger, R. Hermens, J. Hullu (2015)Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study
BMC Cancer, 15
M. Sherman, M. Piedmonte, P. Mai, O. Ioffe, B. Ronnett, L. Le, Iouri Ivanov, M. Bell, S. Blank, P. DiSilvestro, C. Hamilton, K. Tewari, K. Wakeley, N. Kauff, S. Yamada, G. Rodriguez, S. Skates, D. Alberts, Joan Walker, L. Minasian, K. Lu, M. Greene (2014)Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 29
Angie Tong, Scott Kelly, Rachel Nusbaum, K. Graves, B. Peshkin, H. Valdimarsdottir, M. Wood, W. Mckinnon, J. Garber, S. McCormick, Lina Jandorf, M. Schwartz (2015)Intentions for risk‐reducing surgery among high‐risk women referred for BRCA1/BRCA2 genetic counseling
M. Daly, J. Axilbund, S. Buys, B. Crawford, C. Farrell, S. Friedman, J. Garber, S. Goorha, S. Gruber, H. Hampel, V. Kaklamani, W. Kohlmann, Allison Kurian, J. Litton, P. Marcom, R. Nussbaum, K. Offit, T. Pal, B. Pasche, R. Pilarski, Gwen Reiser, K. Shannon, Jeffrey Smith, E. Swisher, J. Weitzel (2010)Genetic/familial high-risk assessment: breast and ovarian.
Journal of the National Comprehensive Cancer Network : JNCCN, 8 5
A. McCarthy, A. Menke, P. Ouyang, K. Visvanathan (2012)Bilateral Oophorectomy, Body Mass Index, and Mortality in U.S. Women Aged 40 Years and Older
Cancer Prevention Research, 5
J. Carlson, A. Miron, E. Jarboe, M. Parast, M. Hirsch, Yonghee Lee, M. Muto, D. Kindelberger, C. Crum (2008)Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 25
D. Kindelberger, Yonghee Lee, A. Miron, M. Hirsch, C. Feltmate, F. Medeiros, M. Callahan, Elizabeth Garner, R. Gordon, C. Birch, R. Berkowitz, M. Muto, C. Crum (2007)Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship
The American Journal of Surgical Pathology, 31
S. Labidi-Galy, E. Papp, Dorothy Hallberg, N. Niknafs, V. Adleff, Michael Noe, Rohit Bhattacharya, M. Novak, Siân Jones, J. Phallen, C. Hruban, M. Hirsch, Douglas Lin, L. Schwartz, Cecile Maire, J. Tille, M. Bowden, A. Ayhan, Laura Wood, R. Scharpf, R. Kurman, Tian-Li Wang, I. Shih, R. Karchin, R. Drapkin, V. Velculescu (2017)High grade serous ovarian carcinomas originate in the fallopian tube
Nature Communications, 8
J. Lamb, Rochelle Garcia, B. Goff, P. Paley, E. Swisher (2006)Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
American journal of obstetrics and gynecology, 194 6
P. Pinsky, Kelly Yu, B. Kramer, A. Black, S. Buys, E. Partridge, J. Gohagan, C. Berg, P. Prorok (2016)Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up.
Gynecologic oncology, 143 2
M. Callahan, C. Crum, F. Medeiros, D. Kindelberger, J. Elvin, J. Garber, C. Feltmate, R. Berkowitz, M. Muto (2007)Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 25
W. Parker, M. Broder, E. Chang, D. Feskanich, C. Farquhar, Zhi-man Liu, D. Shoupe, J. Berek, S. Hankinson, J. Manson (2009)Ovarian Conservation at the Time of Hysterectomy and Long-Term Health Outcomes in the Nurses’ Health Study
Obstetrics & Gynecology, 113
Karen Lu, J. Garber, Daniel Cramer, William Welch, J. Niloff, Deborah Schrag, Ross Berkowitz, M. Muto (2000)Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 14
H. Falconer, L. Yin, H. Grönberg, D. Altman (2015)Ovarian cancer risk after salpingectomy: a nationwide population-based study.
Journal of the National Cancer Institute, 107 2
Ian Jacobs, U. Menon, Andy Ryan, A. Gentry-Maharaj, M. Burnell, Jatinderpal Kalsi, N. Amso, S. Apostolidou, E. Benjamin, D. Cruickshank, Danielle Crump, S. Davies, A. Dawnay, Stephen Dobbs, Gwendolen Fletcher, J. Ford, Keith Godfrey, Richard Gunu, M. Habib, Rachel Hallett, J. Herod, H. Jenkins, C. Karpinskyj, Simon Leeson, S. Lewis, William Liston, Alberto Lopes, T. Mould, John Murdoch, David Oram, D. Rabideau, Karina Reynolds, Ian Scott, M. Seif, Aarti Sharma, Naveena Singh, Julie Taylor, Fiona Warburton, Martin Widschwendter, K. Williamson, R. Woolas, Lesley Fallowfield, Alistair McGuire, S. Campbell, Mahesh Parmar, S. Skates (2016)Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial
Lancet (London, England), 387
W. Rocca, J. Bower, D. Maraganore, J. Ahlskog, B. Grossardt, M. Andrade, L. Melton (2007)Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause
C. Powell, Elizabeth Swisher, I. Cass, Jane McLennan, B. Norquist, Rochelle Garcia, J. Lester, B. Karlan, Lee-may Chen (2013)Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy.
Gynecologic oncology, 129 2
S. Domchek, T. Friebel, C. Singer, D. Evans, H. Lynch, C. Isaacs, J. Garber, S. Neuhausen, E. Matloff, R. Eeles, G. Pichert, Laura t'veer, N. Tung, J. Weitzel, F. Couch, W. Rubinstein, P. Ganz, M. Daly, O. Olopade, G. Tomlinson, J. Schildkraut, J. Blum, T. Rebbeck (2010)Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
JAMA, 304 9
P. Mai, M. Piedmonte, Paul Han, Richard Moser, J. Walker, G. Rodriguez, J. Boggess, Thomas Rutherford, O. Zivanovic, David Cohn, J. Thigpen, R. Wenham, Michael Friedlander, Chad Hamilton, J. Bakkum-Gamez, A. Olawaiye, M. Hensley, Mark Greene, Helen Huang, L. Wenzel (2017)Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study.
Obstetrical & Gynecological Survey
J. Press, Kaitlyn Wurz, B. Norquist, Ming Lee, C. Pennil, Rochelle Garcia, P. Welcsh, B. Goff, E. Swisher (2010)Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers.
Neoplasia, 12 12
I. Cass, C. Holschneider, Nandini Datta, D. Barbuto, A. Walts, B. Karlan (2005)BRCA-Mutation–Associated Fallopian Tube Carcinoma: A Distinct Clinical Phenotype?
Obstetrics & Gynecology, 106
G. Cicero, R. Luca, Patrizia Dorangricchia, G. Coco, C. Guarnaccia, D. Fanale, V. Caló, A. Russo (2017)Risk Perception and Psychological Distress in Genetic Counselling for Hereditary Breast and/or Ovarian Cancer
Journal of Genetic Counseling, 26
Emily Meserve, J. Mirkovic, J. Conner, Eric Yang, M. Muto, N. Horowitz, K. Strickland, B. Howitt, C. Crum (2017)Frequency of "incidental" serous tubal intraepithelial carcinoma (STIC) in women without a history of or genetic risk factor for high-grade serous carcinoma: A six-year study.
Gynecologic oncology, 146 1
Katherine Leeper, Rochelle Garcia, E. Swisher, B. Goff, B. Greer, P. Paley (2002)Pathologic findings in prophylactic oophorectomy specimens in high-risk women.
Gynecologic oncology, 87 1
Salpingectomy with interval oophorectomy has gained traction as an ovarian cancer prevention strategy, but is not currently recommended for high risk women. Nevertheless, some choose this approach. We aimed to understand risk perception and plans for oophorectomy in BRCA1 and BRCA2 (BRCA) mutation carriers choosing salpingectomy for ovarian cancer prevention. This was a longitudinal survey study of BRCA mutation carriers who underwent bilateral salpingectomy to reduce ovarian cancer risk. An initial written questionnaire and telephone interview was followed by annual phone interviews. 22 women with BRCA mutations were enrolled. Median follow-up was three years. The median age at salpingectomy was 39.5 years (range 27–49). Perceived lifetime ovarian cancer risk decreased by half after salpingectomy (median risk reduction 25%, range 0–40%). At final follow-up, five (22.7%) had undergone oophorectomy and five women (22.7%) were not planning to undergo completion oophorectomy. BRCA mutation carriers who had salpingectomy after the recommended age of prophylactic surgery (vs. before the recommended age) were less likely to plan for future oophorectomy (28.6% vs. 66.7%, p = 0.037). All women were satisfied with their decision to undergo salpingectomy with eighteen (81.8%) expressing decreased cancer-related worry. There were no diagnoses of ovarian cancer during our study period. In conclusion, most BRCA mutation carriers undergoing risk-reducing salpingectomy are satisfied with their decision and have lower risk perception after salpingectomy, though some older mutation carriers did not plan on future oophorectomy. Salpingectomy with delayed oophorectomy in BRCA mutation carriers remains investigational and should preferably be performed within a clinical trial to prevent introduction of an innovation before safety has been proven.
Familial Cancer – Springer Journals
Published: Apr 24, 2020
Access the full text.
Sign up today, get DeepDyve free for 14 days.